Element Biosciences logs 100 DNA sequencer orders as it gains momentum in a competitive market
Element Biosciences has reported 100 commercial orders of its benchtop DNA sequencer, a figure that outside observers called solid progress as the startup competes for customers in a market dominated by Illumina.
Molly He, Element’s CEO, said the majority of the orders have already been shipped, and Element plans to get the rest out by the end of the year. Element has customers in the US and 13 other countries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.